Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice

PURPOSE: Accumulating evidence suggests that not all cancer chemotherapy patients who receive first-cycle pegfilgrastim prophylaxis continue to receive it in subsequent cycles and that these patients may be subsequently at higher risk of febrile neutropenia (FN). Additional evidence from US clinical...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Support Care Cancer
Prif Awduron: Weycker, Derek, Li, Xiaoyan, Barron, Rich, Li, Yanli, Reiner, Maureen, Kartashov, Alex, Figueredo, Jacqueline, Tzivelekis, Spiros, Garcia, Jacob
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2015
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846701/
https://ncbi.nlm.nih.gov/pubmed/26670915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-015-3039-4
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg